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Liver nodular regenerative hyperplasia after
bone marrow transplant
We report an unusual liver disease which may
occur after bone marrow transplantation, i.e. the
collapse of hepatic lobuli followed by regenerative
islets: the resulting clinical picture may mimic GvHD
or a viral disease, but histology is diagnostic, show-
ing nodular regeneration in the absence of inflam-
mation or fibrosis.
Sir,
Liver abnormalities are frequently detected after
bone marrow transplantation (BMT). Early after the
transplant they may be due to drug toxicity, less fre-
quently to venocclusive disease (VOD), viral or septic
infection. Late liver impairment is often related to
chronic graft-versus-host disease (GvHD), and less fre-
quently to viral reactivation or drug toxicity. Persisting
disorders are also to be expected in patients who sur-
vive a VOD.1 A rarer post-transplant liver disorder is
nodular regenerative hyperplasia (NRH), which is charac-
terized by the formation of intrahepatic nodules of
regenerating hepatocytes, with moderate or no fibro-
sis. This disorder has been associated with a number
of clinical conditions of  autoimmune (rheumatoid
arthritis; Sjögren's, CREST or Felty's syndrome), hema-
tologic (myelo-and lymphoproliferative disorders), or
endocrine (diabetes mellitus) origin,2 or even after pro-
longed administration of immunosuppressive3 or con-
tracceptive drugs. We report the case of a patient who
had NRH nine months after an allogeneic BMT.
A 35-year old male with chronic myeloid leukemia
in chronic phase received a bone marrow transplant
from his HLA-identical brother in March 1998. The
conditioning regimen was BuCy2; he was infused with
1.6×108/kg. GvHD prophylaxis was a short course of
cyclosporin A and methotrexate (MTX). On day +2,
after the first dose of MTX, the patient developed
weight gain, painful hepatomegaly, decreased  diure-
sis and increased  bilirubin, transaminases and PAI-1.
With the suspicion of an impending VOD, we discon-
tinued MTX and all signs and symptoms disappeared.
On day +33, a grade IV acute cutaneous GvHD
occurred, successfully treated with high dose pred-
nisone. At +5 months the patient presented with
increased ALT, AST, γ-GT, ALP and bilirubin, in the
absence of markers of viral infection. The patient was
thought to have hepatic GvHD, so she underwent liv-
er biopsy, which showed  liver injury probably due to
drug toxicity. All drugs were discontinued, and all liv-
er function parameters improved; however, three
months later a new wave of hepatic cytolysis and
cholestasis  occurred (Figure 1). A repeat  liver biopsy
showed hepatocyte nodular regeneration with com-
pression of the surrounding tissue, in the absence of
inflammatory cells even in portal areas and virtually no
fibrosis. This picture is typical of  NRH (Figure 2 ). No
treatment was planned; liver enzymes are checked
every month and continue to fluctuate. Seven months
after the diagnosis of NRH, no sign of portal hyper-
tension has appeared. 
The pathogenesis of NRH is not well understood.
Probably it results from sinusoidal lesions causing
local hypoperfusion with regenerative hyperplasia in
the normally perfused surrounding areas.4 Clinically,
NRH may be confused with liver cirrhosis.5 Fifty per
cent of patients with NRH develop portal hyperten-
sion.4 Hepatic failure, rupture of the liver, malignant
transformation and gastric antral vascular ectasia
syndrome are described complications of NRH.6,7
It is possible that post-transplant NRH is more fre-
quent than reported, since several cases could have
been clinically misdiagnosed as VOD, GvHD or drug
toxicity.8 Since no clinical or laboratory findings are
specific to NRH, an informative liver biopsy is the
only key to a correct diagnosis.9 In addition, since the
liver may be sequentially involved by a number of dif-
ferent events in the post-transplant period, repeat liv-
er biopsies may be necessary to identify all the dam-
aging mechanisms.
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Figure 1. Post-transplant time course of liver enzymes.
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Incidence of factor v leiden and prothrombin
G20210A in patients submitted to stem cell
transplantation
Factor V Leiden (FVL) and prothrombin G20210A
are the most common defects associated with
thrombophilia. The purpose of our study was to
define the incidence FVL and prothrombin 20210A
in a population of patients with hematologic malig-
nancies submitted to high dose chemotherapy and
stem cell transplantation and verify the role of these
mutations in the development of thrombotic com-
plications during and after transplantation
Sir,
Factor V Leiden (FVL) and prothrombin G20210A
are the most frequent mutations associated with
inherited thrombophilia. They are fairly common in
the general population and exert a substantial risk of
development of thromboses during a subject’s lifes-
pan. The prevalences of FVL and prothrombin
G20210A are 5% and 2%, respectively, in Caucasians1
and 1.8% and 2.8%, respectively, in the general Italian
population.2,3 The relevance of these mutations
prompted us to investigate their prevalence and sig-
nificance in thrombotic complications after stem cell
transplantation (SCT) in patients with hematologic
malignancies.
Sixty-nine consecutive patients referred to our
Transplant Unit were screened for FVL and pro-
thrombin G20210A mutation. Protein C, S and ATI-
II deficiency, and antiphospholipid antibodies were
excluded in this series of patients. The patients’ char-
acteristics are shown in Table 1. Donor-recipient
pairs were studied before allogeneic SCT in order to
avoid bias from post-transplantation chimerism.4
Fifty-four patients are alive after a median follow-
up of 31 months (range 10-69). Two out of 69
patients (2.9%) were heterozygotes for these throm-
bophilic mutations, one for FVL (1.4%) and one for
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Figure 2. Post-transplant liver nodular regenerative hyper-
plasia. A: Two regenerative nodules compressing hepato-
cytes. A portal area (bottom  right) shows moderate fibro-
sis. (HE, 400x). B: Note the absence of inflammatory cells
on the boundary between regenerating and compressed
hepatocytes. (HE 1000x). C: Reticular fibrosis in the com-
pressed areas, revealed by the Gomori’s staining (400x).
